By admin 
The study, which meticulously examined healthy adults with no prior psychedelic experience, represents a significant step forward in understanding how psilocybin interacts with the brain. While none of the participants had a diagnosed mental health condition, the research provides crucial clues about why psilocybin has demonstrated remarkable therapeutic potential in clinical trials for conditions such as depression, anxiety, post-traumatic stress disorder (PTSD), and addiction. These conditions are often characterized by rigid thought patterns, rumination, and dysfunctional neural circuits, areas where psilocybin’s ability to "loosen up" brain activity could be profoundly beneficial.
At the core of the researchers’ investigation was the concept of brain "entropy," a term borrowed from physics that, in neuroscience, describes the variety and unpredictability of neural activity. High entropy indicates a more diverse, flexible, and less constrained pattern of brain activity, suggesting that the brain is exploring a wider range of states and processing information more broadly. The study’s results suggest that this enhanced, more diverse pattern of brain activity may be instrumental in promoting psychological insight and that the psychedelic experience itself plays a critical, perhaps even indispensable, role in mediating psilocybin’s longer-term therapeutic effects.
A particularly striking finding was the direct correlation between a larger rise in brain entropy during the minutes and hours immediately following a high dose of psilocybin and greater emotional insight reported the following day. Participants who experienced more significant increases in insight subsequently described improved well-being a month later, indicating a potential causal pathway: acute neural flexibility leads to psychological breakthroughs, which then translate into sustained improvements in mental health.
"Psychedelic means ‘psyche-revealing,’ or making the psyche visible," explained senior author Robin Carhart-Harris, PhD, the Ralph Metzner Distinguished Professor of Neurology at UCSF and founding director of the Centre for Psychedelic Research at Imperial College London. His expertise in mapping the brain effects of psychedelics has been pivotal in advancing the field. "Our data shows that such experiences of psychological insight relate to an entropic quality of brain activity and how both are involved in causing subsequent improvements in mental health. It suggests that the trip – and its correlates in the brain – is a key component of how psychedelic therapy works." This statement underscores a growing consensus among researchers that the subjective, experiential component of psychedelic use is not merely a side effect but a central mechanism through which these compounds exert their healing properties.
Measuring Psilocybin’s Multifaceted Effects on the Brain
To comprehensively examine psilocybin’s impact, the researchers employed a sophisticated array of neuroimaging techniques and psychological assessments. Measurements were meticulously taken at three critical junctures: prior to the psychedelic dose, during the peak of the experience, and again one month later. This longitudinal design allowed for a robust comparison of acute effects with enduring changes.
The decision to recruit 28 healthy volunteers, free from any diagnosed mental health conditions, was a deliberate and strategic choice. This approach allowed the team to isolate the fundamental effects of psilocybin on brain function and structure without the confounding variables introduced by pre-existing psychiatric illnesses or concurrent medications. This unadulterated view of psilocybin’s neurobiological footprint is invaluable for establishing baseline mechanisms before translating findings to clinical populations. The absence of mental health conditions also permitted the researchers to perform a broader range of non-invasive tests, ensuring a rich dataset.
The experimental protocol was carefully structured. In the first stage, participants received a 1 mg dose of psilocybin, which the researchers designated as a "placebo" dose, as this amount is sub-perceptual and unlikely to induce significant psychedelic effects. Following this, their brain activity was monitored using electroencephalography (EEG), a non-invasive method that records electrical signals generated by the brain through electrodes placed on the scalp. EEG provides excellent temporal resolution, allowing researchers to capture rapid changes in brain activity.
Over the subsequent weeks, participants underwent rigorous psychological evaluations to assess psychological insight, overall well-being, and cognitive performance. To delve deeper into brain activity and connectivity, the researchers also utilized functional MRI (fMRI), which measures changes in blood flow to specific brain regions, reflecting neural activity. Crucially, diffusion tensor imaging (DTI) was employed to examine the structural integrity and connectivity of white matter tracts – the "wiring" that connects different parts of the brain. DTI works by measuring the diffusion of water molecules along these fiber pathways, providing insights into their density and organization.
One month after receiving the placebo dose, the participants entered the second, pivotal stage of the experiment: they were administered 25 mg of psilocybin. This is considered a high dose, reliably capable of producing a powerful and immersive psychedelic experience. Researchers again recorded brain activity with EEG during the peak of the "trip" and repeated the identical battery of psychological and imaging assessments over the following weeks. This elegant crossover design allowed the team to directly compare the effects of a full, consciousness-altering psychedelic dose with those observed after a sub-perceptual control dose, thereby isolating the unique contributions of the psychedelic experience.
Psilocybin’s Inducement of Brain Entropy and Structural Remodeling
The EEG recordings, taken within 60 minutes of the 25 mg dose, revealed a rapid and significant rise in brain entropy. This finding suggests that under the influence of psilocybin, the brain transitions into a state of heightened flexibility and connectivity, generating and processing a broader range of information than in its baseline state. This increased entropic activity aligns with the subjective reports of interconnectedness, novel perspectives, and dissolution of ego often described during psychedelic experiences.
Perhaps the most compelling and novel discovery emerged from the DTI scans conducted one month later. The researchers found measurable signs that neural tracts, particularly those involved in higher-order cognitive functions, were denser and showed greater integrity. This pattern of increased structural integrity is noteworthy because it is typically the reverse of changes commonly associated with aging, where neural tracts tend to become more diffuse and their integrity diminishes. This observation implies a potential "rejuvenating" effect on brain structure, a hypothesis that warrants further investigation.
The researchers prudently emphasized that additional studies are essential to fully elucidate the exact meaning and long-term implications of these structural findings. Nevertheless, they described this result as a previously unseen indication that psychedelics may indeed produce lasting, physical changes in the brain’s white matter architecture, moving beyond purely functional alterations. This discovery opens new avenues for understanding neuroplasticity and the potential for psychedelics to promote neural repair or reorganization.
Lasting Gains in Insight, Well-being, and Cognitive Flexibility
The profound impact of the high-dose psilocybin experience was also evident in the participants’ subjective reports and objective psychological assessments. The day after taking 25 mg of psilocybin, an overwhelming 27 of the 28 participants characterized the experience as the "single most" unusual state of consciousness they had ever encountered. The sole remaining participant ranked it among the five most unusual experiences of their life, underscoring the intensity and uniqueness of the psychedelic state.
Quantitatively, participants reported substantially more psychological insight after the 25 mg dose compared to the 1 mg placebo. This insight manifested as new perspectives on personal issues, enhanced self-awareness, and a deeper understanding of emotional patterns. Crucially, these subjective gains translated into objective improvements in well-being. Measures of well-being, assessed two weeks and four weeks after the high dose, showed significant improvement. These assessments included responses to statements designed to gauge emotional health and life satisfaction, such as, "I’ve been feeling optimistic about the future" and "I’ve been dealing with problems well."
Beyond emotional and psychological gains, the study also revealed cognitive benefits. One month after the experiment, participants demonstrated improved performance on a test of cognitive flexibility. This measure assesses an individual’s ability to adapt their thinking, shift between different concepts, and respond effectively to changing information – a critical component of problem-solving and mental agility. The improvement in cognitive flexibility further supports the hypothesis that psilocybin helps "loosen up stereotyped patterns of brain activity," as articulated by Taylor Lyons, PhD, a research associate at Imperial College London and the first author of the paper. "The fact that these changes track with insight and improved well-being is especially exciting," Lyons noted, highlighting the clinical relevance of these cognitive enhancements.
The Psychedelic Experience: A Driver of Therapeutic Benefits
A pivotal aspect of this research lies in its elucidation of how the psychedelic experience might drive these benefits. The study meticulously mapped the chain of events: participants with the largest increases in brain entropy during the initial minutes and hours after taking psilocybin were also the most likely to report greater insight the next day. These increases in insight were, in turn, strongly associated with more robust improvements in well-being one month later. This finding leads the researchers to conclude that the acute experience of psychological insight, catalyzed by increased brain entropy, appears to be a critical mediator that drives the later, sustained gains in well-being. This challenges purely pharmacological models of action, emphasizing the importance of the subjective "trip" in the therapeutic process.
These findings have profound implications for the nascent field of psychedelic-assisted psychotherapy. They could eventually help clinicians refine psilocybin treatments for individuals grappling with mental health conditions. For instance, understanding the relationship between dose, brain entropy, and insight might enable clinicians to identify an optimal dose that produces sufficient brain entropy to encourage meaningful psychological breakthroughs without creating an unnecessarily overwhelming or intense experience for the patient. This could lead to more personalized and effective treatment protocols, maximizing therapeutic benefit while minimizing discomfort.
"We already knew psilocybin could be helpful for treating mental illness," Carhart-Harris concluded, reflecting on the broader context of psychedelic research. "But now we have a much better understanding of how." This study provides a compelling neurobiological framework for understanding psilocybin’s therapeutic actions, bridging the gap between subjective experience and objective brain changes. It reinforces the idea that the psychedelic journey is not just an altered state of consciousness but a potent catalyst for neural reorganization and profound psychological healing.
The implications of this research extend beyond psilocybin. It provides a blueprint for understanding other psychedelic compounds and their potential to modulate brain function and structure. As the scientific and medical communities continue to explore the therapeutic potential of psychedelics, studies like this are vital for building a robust evidence base, guiding clinical practice, and ultimately integrating these powerful compounds responsibly into mainstream healthcare. While the sample size of 28 healthy volunteers necessitates further research in larger, diverse clinical populations, the initial discovery of lasting physical changes in the brain represents a significant milestone, promising a deeper understanding of neuroplasticity and novel approaches to mental health care.
Authors: Other UCSF authors are Manesh Girn, PhD, Hannes Kettner, and Adam Gazzaley, MD, PhD. For all authors, see the paper.
Funding: This work was funded by philanthropic donations to the Centre for Psychedelic Research, Imperial College London, the Alex Mosley Charitable Trust, and the Beckley Foundation. Carhart-Harris is supported by the Ralph Metzner Distinguished Professorship and philanthropic donations to the Psychedelics Division, Neuroscape, UCSF, plus philanthropic donations to the Carhart-Harris Lab.
